Evolution of HIV integrase resistance mutations

Purpose of review Integrase strand transfer inhibitors (INSTIs) have become a key component of antiretroviral therapy since the approval of twice-daily raltegravir in 2007 and the more recent approval of elvitegravir in 2012. At the same time, a third compound, dolutegravir, is in late-phase clinical trials, being tested as part of a multidrug once-daily formulation comprising this INSTI and two other antiretroviral (ARV) drugs. This review focuses on the factors leading to the development of drug resistance mutations (DRMs) against INSTIs, evidence of cross-resistance among them, and the results of regimen simplification in regard to this topic. Recent findings Sequencing data show that DRMs are highly dynamic in patients failing INSTI therapy. Considerations of viral fitness and drug resistance can together determine the evolution of drug resistance mutations, and in this regard the Y143 and Q148 pathways are superior to the N155 pathway in the promotion of resistance. Preventing the emergence of DRMs requires that effective reverse transcriptase or other inhibitors be used together with INSTIs and that high-level adherence to treatment be maintained. Summary Because of the susceptibility to drug resistance, INSTIs should always be used together with other effective ARV drugs.

[1]  Jeffrey N. Martin,et al.  The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults , 2012, Journal of acquired immune deficiency syndromes.

[2]  Sarah Crunkhorn.  Trial watch: HIV integrase inhibitor-based regimen beats market leader , 2012, Nature Reviews Drug Discovery.

[3]  R. Shafer,et al.  Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations , 2012, PloS one.

[4]  K. White,et al.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks , 2012, The Lancet.

[5]  C. Marchand,et al.  The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet , 2012, Expert opinion on investigational drugs.

[6]  Wei Huang,et al.  Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance In Vivo , 2012, Journal of Virology.

[7]  C. Charpentier,et al.  Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients: Week 96 Results From the ANRS 139 TRIO Trial , 2012, Journal of acquired immune deficiency syndromes.

[8]  M. Wainberg,et al.  Novel therapeutic strategies targeting HIV integrase , 2012, BMC Medicine.

[9]  C. Katlama,et al.  Dolutegravir for the treatment of HIV , 2012, Expert opinion on investigational drugs.

[10]  F. Ceccherini‐Silberstein,et al.  Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. , 2012, The Journal of infectious diseases.

[11]  M. Boyd.  Dolutegravir--a promising antiretroviral in development. , 2012, The Lancet. Infectious diseases.

[12]  K. White,et al.  In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. , 2012, Antiviral research.

[13]  Benjamin Young,et al.  Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. , 2012, The Lancet. Infectious diseases.

[14]  M. Wainberg,et al.  Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir , 2011, Journal of Virology.

[15]  Adriano Lazzarin,et al.  Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. , 2011, The Journal of infectious diseases.

[16]  V. Calvez,et al.  The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. , 2011, The Journal of antimicrobial chemotherapy.

[17]  Yves Pommier,et al.  Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) , 2011, Molecular Pharmacology.

[18]  D. Winslow.  Resistance to HIV integrase inhibitors. , 2011, AIDS alert.

[19]  T. Seki,et al.  Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes , 2011, Antimicrobial Agents and Chemotherapy.

[20]  K. Hertogs,et al.  Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. , 2011, Antiviral research.

[21]  V. Soriano,et al.  Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience. , 2011, Antiviral research.

[22]  Y. Pommier,et al.  Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143 , 2011, AIDS.

[23]  Soo-Yon Rhee,et al.  HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications , 2011, The Journal of infectious diseases.

[24]  M. Wainberg,et al.  Subtype diversity associated with the development of HIV‐1 resistance to integrase inhibitors , 2011, Journal of medical virology.

[25]  C. Hurt.  Article Commentary: Transmitted Resistance to HIV Integrase Strand-Transfer Inhibitors: Right on Schedule , 2011, Antiviral therapy.

[26]  C. Petropoulos,et al.  Transmission of Integrase Strand-Transfer Inhibitor Multidrug-Resistant HIV-1: Case Report and Response to Raltegravir-Containing Antiretroviral Therapy , 2011, Antiviral therapy.

[27]  F. Maldarelli,et al.  Transmitted Raltegravir Resistance in An HIV-1 Crf_Ag-Infected Patient , 2011, Antiviral therapy.

[28]  R. Paredes,et al.  Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. , 2010, Antiviral research.

[29]  Shigeru Miki,et al.  In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor , 2010, Antimicrobial Agents and Chemotherapy.

[30]  Maxwell D. Cummings,et al.  Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance , 2010, Proceedings of the National Academy of Sciences.

[31]  L. Stuyver,et al.  Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates , 2010, Antimicrobial Agents and Chemotherapy.

[32]  M. Wainberg,et al.  HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays , 2010, AIDS.

[33]  D. Hazuda,et al.  Resistance to inhibitors of the human immunodeficiency virus type 1 integration. , 2010, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[34]  Hongtao Xu,et al.  Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor , 2010, Journal of Virology.

[35]  Dominique Schols,et al.  Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. , 2010, Virology.

[36]  D. Hazuda,et al.  Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways , 2009, Journal of Virology.

[37]  C. Charpentier,et al.  Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure , 2009, Antimicrobial Agents and Chemotherapy.

[38]  Zeyu Lin,et al.  Biochemical Analysis of HIV-1 Integrase Variants Resistant to Strand Transfer Inhibitors* , 2008, Journal of Biological Chemistry.

[39]  K. Hertogs,et al.  Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors , 2008, Journal of Virology.

[40]  R. Shafer.  Rationale and uses of a public HIV drug-resistance database. , 2006, The Journal of infectious diseases.

[41]  E. Poveda,et al.  HIV entry inhibitors: mechanisms of action and resistance pathways. , 2006, The Journal of antimicrobial chemotherapy.

[42]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[43]  M. Hirsch,et al.  Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. , 1990, The Journal of infectious diseases.

[44]  Z. Debyser,et al.  Elvitegravir: a once daily alternative to raltegravir. , 2012, The Lancet. Infectious diseases.

[45]  Single-tablet Quad regimen achieves high rate of virologic suppression. , 2010, AIDS patient care and STDs.

[46]  E. Garvey,et al.  S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor , 2009 .

[47]  Patricia A Cane,et al.  Infection and Drug Resistance Dovepress Patterns of Resistance Development with Integrase Inhibitors in Hiv , 2022 .